Adimmune announced its financial report for 2023, with revenue totaling NT$1.785 billion, marking a decrease of 20.72% compared to the previous year. The net loss attributable to the parent company owner amounted to NT$639 million. The loss per share was NT$1.52, indicating a shift from profitability to loss in operations. Adimmune stated that its operations are expected to return to a growth trajectory this year. This includes orders for influenza bulk solution, finished products, and international contract manufacturing. It is estimated that performance will grow by over 20%. New contract manufacturing orders are actively being negotiated and are expected to be finalized gradually in the third and fourth quarters of this year. In response to the warming international economic climate, Adimmune will comprehensively evaluate overseas factory plans, including those in Southeast Asia and other Asian regions, as part of its international market strategy.
Adimmune indicated that last year, due to international geopolitical turmoil, economic downturn, and reduction of inventory by international contract customers, contract orders were lower than expected, resulting in a 20% decrease in revenue compared to the previous year. However, in the first quarter of this year, the company gradually received international orders. According to existing customer estimates, contract orders are expected to grow by over 20% this year. Negotiations for new contract business have been ongoing since the end of last year, and after efforts in the first half of this year, new cooperation orders are expected to be finalized in the third and fourth quarters, providing new momentum for the company's operations.
In terms of influenza vaccines, production of influenza vaccine bulk solution has begun at the Tanzih plant to supply Taiwan's publicly funded, privately purchased, and exported influenza vaccines. An application for certification of the southern hemisphere influenza vaccine was submitted to Brazil at the end of last year, with the earliest expected approval by the end of this year and sales of the southern hemisphere influenza vaccine beginning in 2025. With the overseas influenza orders received this year, including bulk solutions for Eastern European influenza and finished influenza vaccines for Southeast Asia and mainland China, growth has been observed compared to last year.
Furthermore, to expand the production capacity of its subsidiary Antro (6564) for enterovirus vaccines, Adimmune has initiated the conversion of the enterovirus vaccine production line. It is expected that by the end of the year, the enterovirus vaccine production line will be relocated to the Adimmune cell culture plant, increasing capacity several times over. Clinical trials for Antro's enterovirus vaccine in Vietnam have progressed smoothly, with Phase III trials completed, and a complete efficacy evaluation report expected in the third quarter.
Adimmune pointed out that due to the warming economic climate, it will relaunch its overseas market strategy. Among them, the overseas factory plan will take its first step this year through field visits, strategic cooperation, and capacity assessments, based on international customer orders and market demand.
